Ampyra (DrugBank: -)
2 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 1 |
13 | 多発性硬化症/視神経脊髄炎 | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01491022 (ClinicalTrials.gov) | July 2012 | 8/12/2011 | A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease | A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease | Parkinson's Disease | Drug: Ampyra first, then Placebo;Drug: placebo first, then Ampyra | University of Miami | Acorda Therapeutics | Completed | 45 Years | 80 Years | All | 22 | Phase 1;Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01337986 (ClinicalTrials.gov) | May 2011 | 13/4/2011 | Ampyra for Optic Neuritis in Multiple Sclerosis | Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis | Multiple Sclerosis;Optic Neuritis | Drug: Dalfampridine/Placebo;Drug: Placebo/Dalfampridine | Washington University School of Medicine | Acorda Therapeutics | Completed | 18 Years | 55 Years | All | 53 | Phase 2;Phase 3 | United States |
2 | EUCTR2010-023678-38-IT (EUCTR) | 20/04/2011 | 02/02/2011 | High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND | High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND | patients with multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10028245 | Trade Name: MANTADAN*20CPR 100MG INN or Proposed INN: Amantadine Trade Name: AMPYRA INN or Proposed INN: Ampyra | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | NULL | Not Recruiting | Female: yes Male: yes | Italy |